About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Lta/Tnftm1Eug
targeted mutation 1, Hans-Pietro Eugster
MGI:2182273
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Lta/Tnftm1Eug/Lta/Tnftm1Eug B6.129-Lta/Tnftm1Eug MGI:4867499
hm2
Lta/Tnftm1Eug/Lta/Tnftm1Eug involves: 129/Sv MGI:3768383
hm3
Lta/Tnftm1Eug/Lta/Tnftm1Eug involves: 129/Sv * C57BL/6 MGI:4867497
hm4
Lta/Tnftm1Eug/Lta/Tnftm1Eug involves: 129 * C57BL/6J MGI:4867649


Genotype
MGI:4867499
hm1
Allelic
Composition
Lta/Tnftm1Eug/Lta/Tnftm1Eug
Genetic
Background
B6.129-Lta/Tnftm1Eug
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lta/Tnftm1Eug mutation (0 available); any Tnf mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most S. aureus-infected mice die unlike similarly treated wild-type mice (J:115034)
• most S. aureus-infected mice die unlike similarly treated wild-type mice (J:115034)

immune system
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• 28 days after S. aureus infection (J:115034)
• 28 days after S. aureus infection (J:115034)
• from spleen cells of S. aureus-infected mice (J:115034)
• from spleen cells of S. aureus-infected mice (J:115034)
• S. aureus-infected mice exhibit decreased septic arthritis compared with similarly treated wild-type mice (J:115034)
• S. aureus-infected mice exhibit decreased septic arthritis compared with similarly treated wild-type mice (J:115034)
• Staphylococcus aureus-infected mice exhibit greater weight loss, increased mortality, reduced bacterial clearance, decreased IFN-gamma production, decreased septic arthritis, increased IgM serum levels, and decreased antigen-specific IgG serum levels compared with similarly treated wild-type mice (J:115034)
• Staphylococcus aureus-infected mice exhibit greater weight loss, increased mortality, reduced bacterial clearance, decreased IFN-gamma production, decreased septic arthritis, increased IgM serum levels, and decreased antigen-specific IgG serum levels compared with similarly treated wild-type mice (J:115034)
• most S. aureus-infected mice die unlike similarly treated wild-type mice (J:115034)
• most S. aureus-infected mice die unlike similarly treated wild-type mice (J:115034)

skeleton
• S. aureus-infected mice exhibit decreased septic arthritis compared with similarly treated wild-type mice (J:115034)
• S. aureus-infected mice exhibit decreased septic arthritis compared with similarly treated wild-type mice (J:115034)

homeostasis/metabolism
• 28 days after S. aureus infection (J:115034)
• 28 days after S. aureus infection (J:115034)

behavior/neurological
• mice exhibit reduced rapid eye movement (REM) sleep episode frequency compared with wild-type mice (J:103266)
• mice exhibit higher absolute electroencephalogram (EEG) power density non-REM sleep within the slow-wave range compared with wild-type mice (J:103266)
• after sleep deprivation, mice exhibit a greater increase in fast 'slow waves' compared with wild-type mice (J:103266)
• however, a decrease in non-REM sleep episode frequency is compensated by extension of non-REM sleep episode duration (J:103266)
• mice exhibit reduced rapid eye movement (REM) sleep episode frequency compared with wild-type mice (J:103266)
• mice exhibit higher absolute electroencephalogram (EEG) power density non-REM sleep within the slow-wave range compared with wild-type mice (J:103266)
• after sleep deprivation, mice exhibit a greater increase in fast 'slow waves' compared with wild-type mice (J:103266)
• however, a decrease in non-REM sleep episode frequency is compensated by extension of non-REM sleep episode duration (J:103266)

hematopoietic system
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)
• in S.aureus-infected mice (J:115034)




Genotype
MGI:3768383
hm2
Allelic
Composition
Lta/Tnftm1Eug/Lta/Tnftm1Eug
Genetic
Background
involves: 129/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lta/Tnftm1Eug mutation (0 available); any Tnf mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice survive doses of LPS that are 100 times as much as the dose that would kill a wild-type mouse (J:31129)
• mice survive doses of LPS that are 100 times as much as the dose that would kill a wild-type mouse (J:31129)
• mice cannot control a dose Listeria monocytogenes that is tolerated by wild-type mice and eventually die from listeriosis with high liver and spleen titers and large necrotic lesions with boundaries of heavily infected hepatocytes (J:31129)
• mice cannot control a dose Listeria monocytogenes that is tolerated by wild-type mice and eventually die from listeriosis with high liver and spleen titers and large necrotic lesions with boundaries of heavily infected hepatocytes (J:31129)

immune system
• CD3+ T cells are decreased (25%+/-3% compared to 45%+/-3% in wild-type mice) (J:31129)
• peripheral T cells are decreased 2-fold compared to wild-type (J:31129)
• CD3+ T cells are decreased (25%+/-3% compared to 45%+/-3% in wild-type mice) (J:31129)
• peripheral T cells are decreased 2-fold compared to wild-type (J:31129)
• leukocyte cell number is increased 4-fold compared to wild-type (J:31129)
• leukocyte cell number is increased 4-fold compared to wild-type (J:31129)
• 65%+/-4% B220+ B cells compared to 44%+/-2% in wild-type mice (J:31129)
• peripheral B cells are increased 6-fold compared to wild-type (J:31129)
• 65%+/-4% B220+ B cells compared to 44%+/-2% in wild-type mice (J:31129)
• peripheral B cells are increased 6-fold compared to wild-type (J:31129)
• spleen lymphocyte composition and micro-architecture are altered (J:31129)
• the T cell zones are lost and the marginal zone is ill-defined (J:31129)
• spleen lymphocyte composition and micro-architecture are altered (J:31129)
• the T cell zones are lost and the marginal zone is ill-defined (J:31129)
• the marginal zone is ill-defined (J:31129)
• the marginal zone is ill-defined (J:31129)
• mice are unable to mount a primary IgG response to sheep red blood cells (J:31129)
• mice are unable to mount a primary IgG response to sheep red blood cells (J:31129)
• mice cannot control a dose Listeria monocytogenes that is tolerated by wild-type mice and eventually die from listeriosis with high liver and spleen titers and large necrotic lesions with boundaries of heavily infected hepatocytes (J:31129)
• mice cannot control a dose Listeria monocytogenes that is tolerated by wild-type mice and eventually die from listeriosis with high liver and spleen titers and large necrotic lesions with boundaries of heavily infected hepatocytes (J:31129)
• response to VV-WR infection is slightly reduced and to LCMV-ARM is strongly reduced (J:31129)
• when footpads are infected with LCMV-ARM or LCMV-WE they fail to swell as in wild-type mice (J:31129)
• response to VV-WR infection is slightly reduced and to LCMV-ARM is strongly reduced (J:31129)
• when footpads are infected with LCMV-ARM or LCMV-WE they fail to swell as in wild-type mice (J:31129)

hematopoietic system
• CD3+ T cells are decreased (25%+/-3% compared to 45%+/-3% in wild-type mice) (J:31129)
• peripheral T cells are decreased 2-fold compared to wild-type (J:31129)
• CD3+ T cells are decreased (25%+/-3% compared to 45%+/-3% in wild-type mice) (J:31129)
• peripheral T cells are decreased 2-fold compared to wild-type (J:31129)
• leukocyte cell number is increased 4-fold compared to wild-type (J:31129)
• leukocyte cell number is increased 4-fold compared to wild-type (J:31129)
• 65%+/-4% B220+ B cells compared to 44%+/-2% in wild-type mice (J:31129)
• peripheral B cells are increased 6-fold compared to wild-type (J:31129)
• 65%+/-4% B220+ B cells compared to 44%+/-2% in wild-type mice (J:31129)
• peripheral B cells are increased 6-fold compared to wild-type (J:31129)
• spleen lymphocyte composition and micro-architecture are altered (J:31129)
• the T cell zones are lost and the marginal zone is ill-defined (J:31129)
• spleen lymphocyte composition and micro-architecture are altered (J:31129)
• the T cell zones are lost and the marginal zone is ill-defined (J:31129)
• the marginal zone is ill-defined (J:31129)
• the marginal zone is ill-defined (J:31129)




Genotype
MGI:4867497
hm3
Allelic
Composition
Lta/Tnftm1Eug/Lta/Tnftm1Eug
Genetic
Background
involves: 129/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lta/Tnftm1Eug mutation (0 available); any Tnf mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following traumatic brain injury, more mice die than similarly treated wild-type mice (J:61314)
• following traumatic brain injury, more mice die than similarly treated wild-type mice (J:61314)

immune system
• following treatment with MOG, mice exhibit delayed onset, decreased severity of disease, and reduced demyelination but increased number of inflammatory foci compared with similarly treated wild-type mice (J:115225)
• following treatment with MOG, mice exhibit delayed onset, decreased severity of disease, and reduced demyelination but increased number of inflammatory foci compared with similarly treated wild-type mice (J:115225)
• mice treated with Plasmodium berghei ANKA (PbA)-infected erythrocytes fail to develop cerebral malaria or vascular leakiness unlike similarly treated wild-type mice (J:37696)
• however, mice treated with PbA-infected with erythrocytes exhibit weight loss, anemia, high parasitemia, and die between 15 and 20 days post-infection (J:37696)
• mice treated with Plasmodium berghei ANKA (PbA)-infected erythrocytes fail to develop cerebral malaria or vascular leakiness unlike similarly treated wild-type mice (J:37696)
• however, mice treated with PbA-infected with erythrocytes exhibit weight loss, anemia, high parasitemia, and die between 15 and 20 days post-infection (J:37696)

homeostasis/metabolism
• following traumatic brain injury, more mice die than similarly treated wild-type mice (J:61314)
• however, traumatic brain injury-induced blood brain barrier disfunction and accumulation of polymononuclear leukocytes is normal (J:61314)
• following traumatic brain injury, more mice die than similarly treated wild-type mice (J:61314)
• however, traumatic brain injury-induced blood brain barrier disfunction and accumulation of polymononuclear leukocytes is normal (J:61314)




Genotype
MGI:4867649
hm4
Allelic
Composition
Lta/Tnftm1Eug/Lta/Tnftm1Eug
Genetic
Background
involves: 129 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lta/Tnftm1Eug mutation (0 available); any Tnf mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)
• whether fed standard chow or a high cholesterol diet (J:112797)
• whether fed standard chow or a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

liver/biliary system
• after 12 weeks on a high cholesterol diet (J:112797)
• after 12 weeks on a high cholesterol diet (J:112797)
• after 12 weeks on a high cholesterol diet (J:112797)
• after 12 weeks on a high cholesterol diet (J:112797)
• after 12 weeks on a high cholesterol diet (J:112797)
• after 12 weeks on a high cholesterol diet (J:112797)

skeleton
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

cardiovascular system
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

homeostasis/metabolism
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

immune system
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

limbs/digits/tail
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)

hematopoietic system
• when fed a high cholesterol diet (J:112797)
• when fed a high cholesterol diet (J:112797)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/26/2016
MGI 6.02
The Jackson Laboratory